The discoveries of EGFR mutations and ALK rearrangements as actionable oncogenic
drivers in non-small-cell lung cancer (NSCLC) has propelled a biomarker-directed treatment …

Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) are the preferential
options for advanced non-small cell lung cancer (NSCLC) patients harboring EGFR …

Details on diagnostic procedures are covered in the Supplementary Material Section 2,
available at https://doi. org/10.1016/j. annonc. 2022.12. 009. See Supplementary Figure S1 …

Epidermal growth factor receptor (EGFR) mutations typically occur in exons 18–21 and are
established driver mutations in non-small cell lung cancer (NSCLC),–. Targeted therapies …

Osimertinib, an epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI),
potently and selectively inhibits EGFR-TKI-sensitizing and EGFR T790M resistance …

Osimertinib is an irreversible, third-generation epidermal growth factor receptor (EGFR)
tyrosine kinase inhibitor that is highly selective for EGFR-activating mutations as well as the …

Targeted therapy with epidermal growth factor receptor (EGFR)‑tyrosine kinase inhibitors
(TKIs) is a standard modality of the 1st‑line treatments for patients with advanced EGFR …

Purpose: Patterns of resistance to first-line osimertinib are not well-established and have
primarily been evaluated using plasma assays, which cannot detect histologic …

Advances in biomarkers, targeted therapies, and immuno-oncology have transformed the
clinical management of patients with advanced NSCLC. For oncogene-driven tumors, there …

Lung cancer is the leading cause of cancer-related mortality worldwide. Although the
PI3K/Akt/mTOR signaling pathway has recently been considered as one of the most altered …